Patents by Inventor Xiaofang Wang
Xiaofang Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12037908Abstract: A method for monitoring and analyzing large tunnel machines based on automatic collection of big data includes the following steps: dividing a tunnel operation area, obtaining environmental information of a tunnel operation sub-area, analyzing rock drilling difficulty of the tunnel operation sub-area, confirming a tunnel operation trajectory, analyzing conformity of the tunnel operation sub-area, processing an abnormal tunnel operation sub-area, and analyzing health state of a tunnel rock drill. According to the present disclosure, a rock drilling difficulty coefficient of each tunnel operation sub-area is used to analyze a corresponding steel rotating speed, and then the tunnel operation trajectory is confirmed. After the tunnel operation is completed, the operation conformity of each tunnel operation sub-area is analyzed, and each abnormal tunnel operation sub-area is screened out and processed accordingly.Type: GrantFiled: December 13, 2023Date of Patent: July 16, 2024Assignees: CHINA TIESIJU CIVIL ENGINEERING GROUP CO., LTD., ANHUI DIGITAL INTELLIGENT CONSTRUCTION RESEARCH INSTITUTE CO., LTDInventors: Xiaofang Pei, Heng Wang, Xiang Shen, Liang Li, Lina Xiao, Yuefeng Chu, Lulu Tian, Ren Huang, Shouqiang Yin, Hao Liang, Lidong Yang, Di Liu, Jingyi Wu, Xiaoxu Yang, Kuo Zhang, Kaixuan Li
-
Patent number: 12029776Abstract: The present invention relates to the field of medical technology, in particular to a composition for treating cancer and use and medicament thereof. The composition comprises an SGLT1 inhibitor and a VEGFR2 inhibitor. The present invention finds that SGLT1 interacts with VEGFR2 to promote the development and progression of tumors; the present invention also finds that a composition of a VEGFR2 targeting inhibitor and an SGLT1 inhibitor has a synergistic anti-tumor effect, and the composition of the VEGFR2 targeting inhibitor and the SGLT1 targeting inhibitor can be used in cancer treatment.Type: GrantFiled: August 19, 2020Date of Patent: July 9, 2024Assignee: NEWISH TECHNOLOGY (BEIJING) CO., LTD.Inventors: Zhongjie Sun, Hailong Qi, Ligong Chen, Huangfan Xie, Defang Liu, Xiao E. Yan, Weiwei Li, Xiaofang Wang
-
Patent number: 12019215Abstract: The disclosure provides an optical imaging system, sequentially including a first lens, a second lens, a third lens, a fourth lens, a fifth lens, a sixth lens, a seventh lens and an eighth lens from an object side to an image side along an optical axis, wherein an image-side surface of the seventh lens is a concave surface; the optical imaging system meets the following conditional expressions: TTL/ImgH<1.3, f/EPD<1.8, ImgH>6 mm and 0<R15/f8<0.8, wherein TTL is a distance from an object-side surface of the first lens to an imaging surface of the optical imaging system on the optical axis; ImgH is a half of diagonal length of an effective pixel region on the imaging surface; f is a total effective focal length of the optical imaging system; EPD is an entrance pupil diameter of the optical imaging system.Type: GrantFiled: January 20, 2021Date of Patent: June 25, 2024Assignee: ZHEJIANG SUNNY OPTICAL CO., LTDInventors: Xiaofang Wang, Kaiyuan Zhang, Fujian Dai, Liefeng Zhao
-
Publication number: 20240180131Abstract: The present disclosure belongs to the technical field of antimicrobial peptide (AMP) production, and relates to a medium for breeding a Hermetia illucens larva that produces a highly active antimicrobial peptide (AMP), a breeding method, and an extraction method of an AMP. The present disclosure provides a medium for breeding a Hermetia illucens larva that produces a highly active AMP, including wheat bran, where the medium has a moisture content of 65% to 70%. In the present disclosure, the medium can realize the rapid and effective production of the highly active AMP by the Hermetia illucens larva.Type: ApplicationFiled: July 11, 2023Publication date: June 6, 2024Inventors: Fei WANG, Hui WANG, Qihui ZHANG, Yuliang CHEN, Chaozhong ZHENG, Xiaofang WANG, Leiyu WANG, Jia WU
-
Patent number: 11899175Abstract: The present disclosure discloses an optical imaging lens assembly, sequentially from an object side to an image side along an optical axis, including: a first lens having refractive power, an object-side surface thereof is concave, and an image-side surface thereof is convex; a second lens having refractive power; a third lens having refractive power; a fourth lens having refractive power; a fifth lens having negative refractive power, and an object-side surface thereof is concave; a sixth lens having positive refractive power; and a seventh lens having refractive power. A total effective focal length f of the optical imaging lens assembly and an effective focal length f3 of the third lens may satisfy f3/f>1.49.Type: GrantFiled: November 2, 2020Date of Patent: February 13, 2024Inventors: Wuchao Xu, Kaiyuan Zhang, Xiaofang Wang, Ying Zhou, Fujian Dai, Liefeng Zhao
-
Patent number: 11867880Abstract: The present disclosure discloses an optical imaging system, sequentially from an object side to an image side of the optical imaging system along an optical axis, including: a first lens having refractive power; a second lens having negative refractive power; a third lens having refractive power; a fourth lens having positive refractive power; a fifth lens having refractive power; a sixth lens having refractive power; and a seventh lens having refractive power, a concave object-side surface, and a concave image-side surface. Half of a diagonal length ImgH of an effective pixel area on an imaging plane of the optical imaging system may satisfy ImgH>6.0 mm. A total effective focal length f of the optical imaging system and an entrance pupil diameter EPD of the optical imaging system may satisfy f/EPD<1.9.Type: GrantFiled: September 30, 2020Date of Patent: January 9, 2024Assignee: Zhejiang Sunny Optical Co., LtdInventors: Xiaofang Wang, Biao Xu, Kaiyuan Zhang, Fujian Dai, Liefeng Zhao
-
Patent number: 11768353Abstract: An optical imaging system includes an optical lens group including, sequentially along an optical axis from an object side to an image side, a first lens, a second lens, a third lens, and a fourth lens; a lens barrel, the optical lens group is accommodated in the lens barrel; and a plurality of spacers including at least two spacers disposed between the third lens and the fourth lens; the diameter D of the lens barrel at an end towards the object side and a maximum effective radius DT11 of an object-side surface of the first lens satisfy 2×DT11/D?0.5.Type: GrantFiled: September 21, 2020Date of Patent: September 26, 2023Assignee: ZHEJIANG SUNNY OPTICAL CO., LTDInventors: Xiaofang Wang, Guijie Zhu, Biao Xu, Qi Chen, Kaiyuan Zhang, Fujian Dai, Liefeng Zhao
-
Publication number: 20230251203Abstract: A method for evaluating adverse reaction of sesquiterpenoids in zedoary turmeric oil is performed successively according to the following steps: (1) preparing a hemoglobin (Hb) solution and a to-be-determined solution; (2) taking Hb solutions with a same volume and respectively adding the same volume of the to-be-determined solution or normal saline thereto, mixing well and standing; (3) determining absorbance with a microplate reader, and comparing the absorbance of a to-be-determined solution group with the absorbance of a normal saline group to obtain a value r; wherein if r>1.5, then the result indicates that the concentration of the to-be-determined solution has a risk of causing dyspnea; wherein, r = OD OD Hb ; in the formula, OD is an absorbance at 280 nm wavelength of the to-be-determined solution after interacting with Hb; ODHb, is an absorbance at 280 nm wavelength of a blank control of normal saline after interacting with Hb.Type: ApplicationFiled: April 26, 2021Publication date: August 10, 2023Applicant: BEIJING FRIENDSHIP HOSPITAL, CAPITAL MEDICAL UNIVERSITYInventors: Dan YAN, Yan YAN, Xiaofang WANG, Zhenzhen WANG
-
Publication number: 20230104993Abstract: A technology of 3D printing integration of hard materials and cells, a preparation of bone-repair functional module with osteogenic microenvironment, bone organoid method and the application of quick repair of bone defects are provided. A preparation method of biological microenvironmental factors as independent osteogenic factors is further provided. The present integrated 3D printing technology realizes 3D printing of cells and hard materials synchronously by adjusting the temperature, so as to build a real sense of biomimetic bone tissue, which can be customized according to the specific defects and clinical needs of patients.Type: ApplicationFiled: September 30, 2022Publication date: April 6, 2023Applicant: CHONGQING MEDICAL UNIVERSITYInventors: Xiaolin TU, Yufei MA, Jun LI, Xian LI, Zhurong TANG, Zhengsong XIE, Jie CHEN, Xiaofang WANG, Guangliang LIU, Pengtao WANG, Bo WANG, Yisheng LUO, Yangxi LIU, Weimin GONG, Molin LI
-
Publication number: 20230089073Abstract: Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.Type: ApplicationFiled: January 27, 2022Publication date: March 23, 2023Inventors: Xiaohui DU, Ray Fucini, Xu Ran, Chien-Hung Yeh, Xiang Zhou, Rui Gao, Joon Won Jeong, Li Liu, Subas Man Sakya, Xiaofang Wang, Hiroyuki Kawai, Craig Lee, David Lloyd, Stig Hansen
-
Patent number: 11573398Abstract: The present disclosure discloses an optical imaging lens group including, sequentially from an object side to an image side along an optical axis, a first lens having positive refractive power with a convex object-side surface; a second lens having refractive power; a third lens having refractive power; a fourth lens having refractive power; a fifth lens having refractive power; and a sixth lens having negative refractive power with a concave object-side surface and a convex image-side surface. A total effective focal length f of the optical imaging lens group, an entrance pupil diameter EPD of the optical imaging lens group and half of a maximal field-of-view Semi-FOV of the optical imaging lens group satisfy: f/EPD<2, and f*tan(Semi-FOV)>4.5 mm.Type: GrantFiled: August 18, 2020Date of Patent: February 7, 2023Assignee: Zhejiang Sunny Optical Co., Ltd.Inventors: Biao Xu, Kaiyuan Zhang, Xiaofang Wang, Fujian Dai, Liefeng Zhao
-
Patent number: 11548849Abstract: The present invention provides novel compounds (e.g., compounds of Formula I) which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.Type: GrantFiled: July 30, 2020Date of Patent: January 10, 2023Assignee: H. Lundbeck A/SInventors: Mario Rottlander, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen, Anette Graven Sams, Krestian Larsen
-
Patent number: 11547685Abstract: This document provides methods and materials for treating polycystic diseases such as polycystic kidney disease. For example, methods for using a TRPV2 agonist (e.g., probenecid) and optionally a vasopressin receptor antagonist (e.g., tolvaptan) to treat a mammal having polycystic kidney disease (e.g., autosomal dominant polycystic kidney disease) are provided.Type: GrantFiled: December 6, 2018Date of Patent: January 10, 2023Assignee: Mayo Foundation for Medical Education and ResearchInventors: Vicente E. Torres, Fouad T. Chebib, Peter C. Harris, Xiaofang Wang
-
Publication number: 20220396569Abstract: Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.Type: ApplicationFiled: May 3, 2022Publication date: December 15, 2022Inventors: Xiaohui DU, Ray FUCINI, Xu RAN, Chien-Hung YEH, Xiang ZHOU, Subas Man SAKYA, Xiaofang WANG, Hiroyuki KAWAI, Craig LEE, Sumanta GARAI
-
Publication number: 20220380300Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.Type: ApplicationFiled: July 20, 2022Publication date: December 1, 2022Applicant: H. Lundbeck A/SInventors: Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen
-
Publication number: 20220323470Abstract: The present disclosure relates to the field of medical technology, and in particular to a composition and the use thereof in the manufacture of a medicament for treating cancer. The present disclosure provides a composition containing a compound of formula I or a pharmaceutically acceptable salt, dimer or trimer thereof, and a tyrosine kinase activity inhibitor. The present disclosure shows through in vivo and in vitro anti-tumor tests that, based on the inhibitory effect of the tyrosine kinase activity inhibitor targeting VEGFR, EGFR and other receptor tyrosine kinases, the combination of Sotagliflozin and a tyrosine kinase activity inhibitor may exhibit a synergistic inhibitory effect on tumors, and the efficacy of the combination is significantly better than that of a single drug.Type: ApplicationFiled: August 19, 2020Publication date: October 13, 2022Applicant: NEWISH TECHNOLOGY (BEIJING) CO., LTD.Inventors: Hailong QI, Xiaofang WANG, Zhongjie SUN
-
Publication number: 20220313652Abstract: The present disclosure relates to the field of medical technology, and in particular to use of a compound of formula I or a pharmaceutically acceptable salt, dimer or trimer thereof in the manufacture of a medicament for treating cancer. By testing the inhibitory effect on a variety of tumor cells, the results show that the compound of formula I has an inhibitory effect on tumor cells, with an IC50 of 40.77 ?M-182.5 ?M. In animal experiments, the compound of formula I shows a good inhibition effect on tumor volume, which is very significantly different from that of the solvent control group, p<0.05.Type: ApplicationFiled: August 19, 2020Publication date: October 6, 2022Applicant: NEWISH TECHNOLOGY (BEIJING) CO., LTD.Inventors: Zhongjie SUN, Xiaofang WANG, Hailong QI
-
Publication number: 20220305072Abstract: The present invention relates to the field of medical technology, in particular to a composition for treating cancer and use and medicament thereof. The composition comprises an SGLT1 inhibitor and a VEGFR2 inhibitor. The present invention finds that SGLT1 interacts with VEGFR2 to promote the development and progression of tumors; the present invention also finds that a composition of a VEGFR2 targeting inhibitor and an SGLT1 inhibitor has a synergistic anti-tumor effect, and the composition of the VEGFR2 targeting inhibitor and the SGLT1 targeting inhibitor can be used in cancer treatment.Type: ApplicationFiled: August 19, 2020Publication date: September 29, 2022Applicant: NEWISH TECHNOLOGY (BEIJING) CO., LTD.Inventors: Zhongjie SUN, Hailong QI, Ligong CHEN, Huangfan XIE, Defang LIU, Xiaoe E. YAN, Weiwei LI, Xiaofang WANG
-
Publication number: 20220280455Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.Type: ApplicationFiled: July 30, 2020Publication date: September 8, 2022Applicant: H. Lundbeck A/SInventors: Anette Graven Sams, Mario Rottlãnder, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen, Jesper Frank Bastlund, Jelena Ivkovic, Karina Krøjer Søby, Morten Grupe Larsen
-
Patent number: 11434199Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.Type: GrantFiled: February 4, 2020Date of Patent: September 6, 2022Assignee: H. Lundbeck A/SInventors: Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen